Company Overview and News
CALGARY, Alberta, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Alaris Royalty Corp. ("Alaris" or the "Corporation") (TSX: AD) is pleased to announce that it has contributed US$46,000,000 (the “BCC Contribution”) to a new partner, Body Contour Centers, LLC (“BCC”), and has committed to contributing an additional US$45,000,000 (the “Additional BCC Contributions”) to BCC in two future tranches dependent on BCC achieving certain financial targets.
2018-07-24 reuters - 1
SAN FRANCISCO, July 24 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX fell 30.71 points, or 0.19 percent, to 16,390.13. * Leading the index were Advantage Oil & Gas Ltd, up 9.0 percent, First Quantum Minerals Ltd, up 5.8 percent, and Alaris Royalty Corp , higher by 5.3 percent. * Lagging shares were Torex Gold Resources Inc, down 9.5 percent, Aurora Cannabis Inc, down 7.7 percent, and PrairieSky Royalty Ltd, lower by 6.
ACBFF AD ALARF TXG CGC PSK TWMJF ACB WEED BDRPF FQVLF FQM TORXF PREKF
Good day, ladies and gentlemen, and welcome to the Alaris Royalty Second Quarter 2018 Earnings Conference Call. [Operator Instructions]. As a reminder, this conference may be recorded. I would now like to turn the conference over to Mr. Curtis Krawetz, Vice President of Investor Relations. Sir, you may begin.
PLNT AD ALARF
Here's your July 2018 Monthly-Paid (MoPay) Small-Mid-Large Cap Dividend, Yield, Upsides, and Net Gains Report. Nano-Cap MoPays are not listed.
SCA "NHF" AD ALARF CRIUF ORC MHIVF RA OXLCO OXLCN SCM RNW CJR.B ECC ECCZ AGNC AHOTF DR.DB.A ECCY TRSWF DR CGIFF MFCSF PSEC OXLC ECCB CJREF SCQ ECCA SUNS GNL PBB
CALGARY, Alberta, July 23, 2018 (GLOBE NEWSWIRE) -- Alaris Royalty Corp. (“Alaris” or the "Corporation") is pleased to announce its results for the three and six months ended June 30, 2018. The results are prepared under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).
Monthly Paying (MoPay) dividend equities make dividend payouts to shareholders twelve times a year instead once, twice, or four times.
CCAOF CJ FFN CBL NAF.UN CRLFF AD ALARF CRIUF MHIVF CHW.DB CJR.B CHW EFRTF AHOTF CNDCF GXOCF BK CHWWF CGIFF DVSPF CJREF GXO FNCSF
CALGARY, Alberta, July 03, 2018 (GLOBE NEWSWIRE) -- Alaris Royalty Corp. ("Alaris" or the "Corporation") (TSX:AD) is announcing today that End of the Roll Carpet & Vinyl (“EOR”) has repurchased Alaris’ financial interests in EOR for $12.60 million (the “EOR Repurchase”). Alaris’ original investment into EOR was in May 2005 for $7.20 million and over the last 13 years Alaris has collected approximately $16.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET